首页> 外文期刊>Annals of geriatric medicine and research. >Serum Hepatitis B Virus DNA Quantitative Analysis Using Polymerase Chain Reaction in Patients with Chronic Hepatits B Virus Infection
【24h】

Serum Hepatitis B Virus DNA Quantitative Analysis Using Polymerase Chain Reaction in Patients with Chronic Hepatits B Virus Infection

机译:聚合酶链反应对慢性乙型肝炎病毒感染患者的血清乙型肝炎病毒DNA定量分析

获取原文
           

摘要

Background :The treatment using more potent antiviral agents for the hepatitis B virus (HBV) infection has been performed widely and a highly sensitive quantification method using the polymerase chain reaction (PCR) that measures the HBV viral genome in sera is available. In this study, the HBV DNA level in each disease status including the inactive HBsAg carrier is evaluated. Method :Samples were obtained from 227 patients with chronic HBV infection that were grouped into chronic hepatitis (111), liver cirrhosis (71), and inactive HBsAg carrier (45). Quantification of HBV DNA was performed using the automated Cobas Amplicor HBV monitor testTM. Result :Among the chronic hepatitis B group (9.76×107 copies/mL), the liver cirrhosis group (4.88 ×105 copies/mL), and the inactive carrier group (3.18×103 copies/mL), the medians of serum HBV DNA levels were significantly different from one group to another (P=0.000). Also, the median of HBV DNA levels in the patients with positive HBeAg (1.77×108 copies/mL) was significantly higher than that of negative HBeAg (2.71×104 copies/mL) (P=0.000). In the patients with negative HBeAg, HBV DNA level in the inactive carrier group (Median 3.18×103 copies/mL) was significantly lower than that of the chronic hepatitis group (Median 2.2× 105 copies/mL (P=0.000). Conclusion :The serum HBV DNA level varied among different disease groups, particularly according to HBeAg positivity. 40% of the chronic hepatitis group with negative HBeAg had HBV DNA levels below 105 copies/mL. Therefore, the quantitative analysis of HBV DNA using this sensitive and automated PCR method would be useful in detecting viral proliferation.
机译:背景:使用更有效的抗病毒剂治疗乙型肝炎病毒(HBV)的治疗已广泛开展,并且可以使用一种可测量血清中HBV病毒基因组的聚合酶链反应(PCR)进行高度灵敏的定量方法。在这项研究中,评估了包括无活性HBsAg载体在内的每种疾病状态下的HBV DNA水平。方法:从227例慢性HBV感染患者中获得的样本分为慢性肝炎(111),肝硬化(71)和无活性HBsAg携带者(45)。使用自动Cobas Amplicor HBV监测仪testTM对HBV DNA进行定量。结果:在慢性乙型肝炎组(9.76×107拷贝/ mL),肝硬化组(4.88×105拷贝/ mL)和无活性载体组(3.18×103拷贝/ mL)中,血清HBV DNA的中位数一组之间的水平显着不同(P = 0.000)。而且,HBeAg阳性患者的HBV DNA水平中位数(1.77×108拷贝/ mL)显着高于阴性HBeAg患者(2.71×104拷贝/mL)(P=0.000)。在HBeAg阴性的患者中,非活动携带者组的HBV DNA水平(中位数为3.18×103拷贝/ mL)显着低于慢性肝炎组(中位数为2.2×105拷贝/mL,P=0.000)。血清HBV DNA水平在不同疾病组之间存在差异,特别是根据HBeAg阳性率而不同;慢性HBeAg阴性的慢性肝炎组中有40%的HBV DNA水平低于105拷贝/ mL,因此,使用这种灵敏,自动化的方法对HBV DNA进行定量分析PCR方法将对检测病毒增殖有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号